文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

前哨淋巴结清扫筛选临床淋巴结阴性前列腺癌患者接受盆腔放疗:对生化复发和系统进展的影响

Sentinel Lymph Node Dissection to Select Clinically Node-negative Prostate Cancer Patients for Pelvic Radiation Therapy: Effect on Biochemical Recurrence and Systemic Progression.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-10-19

本研究评估机器人辅助腹腔镜前哨淋巴结清扫(SLND)筛选可从盆腔外照射放疗和长期雄激素剥夺治疗(ADT)中获益的前列腺癌患者。224例临床淋巴结阴性患者接受放射性同位素引导SLND,pN1患者接受盆腔淋巴结放疗联合3年ADT。结果显示SLND分期准确性高、并发症率低,pN1患者5年无生化复发率和无转移生存率分别为43%和66.6%。

要点

  • SLND并发症率仅8.9%,分期准确性高。
  • pN1患者5年无生化复发率43%,无转移生存率66.6%。
  • SLN活检可作为pN1患者强化盆腔放疗和ADT的筛选工具。

核心结论

  • 放射性同位素引导SLND分期准确性高且并发症率低。
  • 在生化复发预测较低四分位组中观察到的优于预期结局,提示SLN活检可作为pN1患者加用盆腔放疗和ADT强化的潜在筛选工具。

研究设计与样本

  • 回顾性研究,224例临床淋巴结阴性前列腺癌患者接受放射性同位素引导SLND,计划接受外照射放疗。
  • pN1患者接受盆腔淋巴结放疗联合3年ADT,回顾性计算生化复发、总生存和无转移生存率。

主要发现

  • 中位PSA为15.4 ng/mL(IQR 8-29),共切除834枚SLN(中位3枚/患者,IQR 2-5)。
  • 42%患者诊断淋巴结转移,150枚SLN受累(中位1枚,IQR 1-2)。
  • pN0患者5年无生化复发率和无转移生存率分别为67.9%和87.8%,pN1患者分别为43%和66.6%。
  • PSA水平和切除SLN数量是BCR和MFS的独立预测因素,pN状态是BCR的额外独立预测因素。
  • 5年总生存率为97.6%,仅与pN状态相关;Briganti列线图预测准确性为0.665。

关键数值与推荐

  • pN1患者接受盆腔淋巴结放疗联合3年ADT。
  • SLND并发症率为8.9%。

临床怎么用

  • SLND可用于临床淋巴结阴性前列腺癌患者的分期,以筛选适合盆腔放疗和ADT强化的pN1患者。

局限性

  • 回顾性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the efficacy of robotic-assisted laparoscopic sentinel lymph node (SLN) dissection (SLND) to select those patients with prostate cancer (PCa) who would benefit from additional pelvic external beam radiation therapy and long-term androgen deprivation therapy (ADT). METHODS AND MATERIALS: Radioisotope-guided SLND was performed in 224 clinically node-negative patients scheduled to undergo external beam radiation therapy. Patients with histologically positive SLNs (pN1) were also offered radiation therapy to the pelvic lymph nodes, combined with 3 years of ADT. Biochemical recurrence (BCR), overall survival, and metastasis-free (including pelvic and nonregional lymph nodes) survival (MFS) rates were retrospectively calculated. The Briganti and Kattan nomogram predictions were compared with the observed pN status and BCR. RESULTS: The median prostate-specific antigen (PSA) value was 15.4 ng/mL (interquartile range [IQR] 8-29). A total number of 834 SLNs (median 3 per patient; IQR 2-5) were removed. Nodal metastases were diagnosed in 42% of the patients, with 150 SLNs affected (median 1; IQR 1-2). The 5-year BCR-free and MFS rates for pN0 patients were 67.9% and 87.8%, respectively. The corresponding values for pN1 patients were 43% and 66.6%. The PSA level and number of removed SLNs were independent predictors of BCR and MFS, and pN status was an additional independent predictor of BCR. The 5-year overall survival rate was 97.6% and correlated only with pN status. The predictive accuracy of the Briganti nomogram was 0.665. Patients in the higher quartiles of Kattan nomogram prediction of BCR had better than expected outcomes. The complication rate from SLND was 8.9%. CONCLUSIONS: For radioisotope-guided SLND, the high staging accuracy is accompanied by low morbidity. The better than expected outcomes observed in the lower quartiles of BCR prediction suggest a role for SLN biopsy as a potential selection tool for the addition of pelvic radiation therapy and ADT intensification in pN1 patients.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Grivas N, Wit E, Pos F, et al. Sentinel Lymph Node Dissection to Select Clinically Node-negative Prostate Cancer Patients for Pelvic Radiation Therapy: Effect on Biochemical Recurrence and Systemic Progression. Int J Radiat Oncol Biol Phys. 2016. PMID: 28068243. doi:10.1016/j.ijrobp.2016.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。